Free Newsletter
Mymetics outlines malaria vaccine approval timeline
Switzerland's Mymetics says that its experimental malaria vaccine could be ready for marketing as early as 2014. CEO Christain Rochet says that clinical trials on the vaccine--obtained from Pevion--have been carried out in Britain and Switzerland as well as developing nations. It should take another three years to complete clinical work on the vaccine, says Rochet, leading the company to conclude that marketing approval could come in six years.
"There is a pressing need for a vaccine against malaria," said the CEO. "Up to 500 million people a year are infected, with a mortality rate of approximately two million each year."
- read the AFP report
Related Articles:
Malaria trials will pay volunteers to get infected
Gates Foundation readies $258M for new malaria programs
Has the Gates Foundation created a malaria 'cartel'?
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceVaccines email newsletter for FREE!
Be the first to comment